Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.3K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.3K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.3K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.3K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

987
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
987
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

663
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
663
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

1.1K
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
1.1K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.8K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Immediate vs. modified-release nifedipine in pregnancy: Incorrect nomenclature is risking drug errors.

Obstetric medicine·2026
Same author

Acute upper gastrointestinal bleeding in the UK: 2022 audit update.

Gut·2025
Same author

Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.

Journal of patient-reported outcomes·2025
Same author

Which first? Surgery or biologic therapy for ileocolic Crohn's disease in the real world.

Expert review of gastroenterology & hepatology·2025
Same author

Hypercoagulation After Hospital Discharge in Acute Severe Ulcerative Colitis: A Prospective Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024

Related Experiment Video

Updated: Apr 8, 2026

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.5K

'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?

Nathan S S Atkinson1, D John M Reynolds2, Simon P L Travis1

  • 1Translational Gastroenterology Unit and Nuffield Department of Experimental Medicine, University of Oxford, Oxford, UK.

Intestinal Research
|July 2, 2015
PubMed
Summary

Proton pump inhibitors (PPIs) can cause low magnesium and calcium levels, often presenting with various symptoms after long-term use. Discontinuation of PPIs resolves these electrolyte imbalances, highlighting the need for clinical awareness.

Keywords:
Adverse eventFatigueHypomagnesaemiaPathophysiologyProton pump inhibitors

More Related Videos

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
11:43

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

11.2K
Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver
08:25

Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver

Published on: August 27, 2021

3.1K

Related Experiment Videos

Last Updated: Apr 8, 2026

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.5K
Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
11:43

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

11.2K
Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver
08:25

Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver

Published on: August 27, 2021

3.1K

Area of Science:

  • Gastroenterology and Nephrology
  • Clinical Pharmacology

Background:

  • Proton pump inhibitors (PPIs) are widely prescribed medications.
  • Since 2006, an association between PPI use and hypomagnesaemia (low magnesium) and hypocalcaemia (low calcium) has been recognized.
  • These electrolyte disturbances can manifest with musculoskeletal, neurological, or cardiac symptoms after prolonged PPI therapy.

Purpose of the Study:

  • To review the association between PPIs and electrolyte disturbances.
  • To discuss the mechanisms underlying PPI-induced hypomagnesaemia.
  • To emphasize the importance of clinical vigilance in diagnosing these under-recognized conditions.

Main Methods:

  • Review of literature on PPIs and electrolyte imbalances.
  • Discussion of cellular mechanisms of magnesium homeostasis.
  • Analysis of factors influencing intestinal magnesium absorption.

Main Results:

  • Hypomagnesaemia and hypocalcaemia are linked to long-term PPI use.
  • Magnesium levels normalize upon PPI discontinuation and recur upon rechallenge.
  • Reduced intestinal magnesium absorption is a key factor in PPI-induced deficiency.
  • Understanding of magnesium transport mechanisms (paracellular and transcellular) is advancing.

Conclusions:

  • PPIs can lead to significant electrolyte disturbances, particularly hypomagnesaemia.
  • Clinical recognition of PPI-associated hypomagnesaemia is crucial for timely diagnosis and management.
  • Further research into risk factors and precise mechanisms is warranted.